Newsroom | 87503 results

Sorted by: Latest
Biotechnology
-

Samenvatting: Crown Bioscience behaalt Green Lab-duurzaamheidscertificering

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, een wereldwijde contractonderzoeksorganisatie (CRO) met hoofdkantoor in de Verenigde Staten en onderdeel van JSR Life Sciences en het in Japan gevestigde JSR Corporation, heeft vandaag aangekondigd dat zijn vestiging in Leiden, Nederland, het hoogste certificeringsniveau heeft behaald in het My Green Lab-certificeringsprogramma. Deze 'groene' certificering is de gouden standaard in best practices voor laboratoriumduurzaamheid. Het My Green Lab-certi...
-

Samenvatting: BeiGene maakt de financiële resultaten van het eerste kwartaal van 2025 bekend en kondigt bedrijfsupdates aan

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), een internationaal oncologiebedrijf dat haar naam zal veranderen in BeOne Medicines, Ltd., maakte vandaag de financiële resultaten van het eerste kwartaal van 2025 bekend en kondigde aan aantal bedrijfsupdates aan. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeld...
-

Bionic Devices Market Report and Company Analysis 2025-2033 Featuring Abbott, Abiomed, Edward Lifesciences, Rewalk, Boston Scientific, Baxter, Cochlear, Medtronic, William Demant, and EKSO Bionics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Bionic Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering. The Bionic Devices Market is projected to expand from US$ 5.74 billion in 2024 to US$ 11.90 billion by 2033. The market is expanding with an estimated CAGR of 8.45% between 2025 and 2033. The growth rate is attributed to the advances made in prosthetics, exoskeletons, and wearable technologies along with rehabilita...
-

bioAffinity Technologies Announces Closing of $3.25 Million Offering

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million....
-

Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom

CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe Thyroid Eye Disease (TED). Affecting approximately 50,000 people in the UK,1 TED is a progressive and potentially vision-threatening condition, which can cause eye bulging, double vision, eye pain, r...
-

Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials

LONDON--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials. https://www.prnewswire.com/news-releases/altesa-biosciences-details-positive-topline-vape...
-

Leading Health Care Experts Highlight Rapid Pace of Innovation in Medicine, MedTech and AI at NHC Symposium

WASHINGTON--(BUSINESS WIRE)--Leading health care and patient advocacy experts outlined the rapid pace of medical innovation at the National Health Council (NHC) Science of Patient Engagement Symposium, and discussed the many ways technology is transforming patient diagnosis, treatment and quality of life. The conference, entitled, Elevating Innovation: Medicine, MedTech, and AI, held May 7-8 at the National Press Club, brings together more than 150 policymakers, researchers, patients and patien...
-

Resumen: Crown Bioscience logra la certificación de sostenibilidad de laboratorio ecológico

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, una organización de investigación por contrato global con sede en los Estados Unidos que forma parte de JSR Life Sciences y de JSR Corporation, con sede en Japón, anunció hoy que su centro de Leiden (Países Bajos) logró el nivel de certificación más alto en el programa My Green Lab Certification. Este nivel de certificación "ecológico" es el criterio de referencia en prácticas recomendadas de sostenibilidad para laboratorios. El programa My Green La...
-

Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA

TOKYO & HYOGO, Japan--(BUSINESS WIRE)--MEDIPAL and JCR announced that the U.S. FDA granted orphan drug designation (ODD) to JR-446, an investigational drug for the treatment of MPS IIIB....
-

Lynch Regenerative Medicine Hires Hee as Chief Scientific Officer

FRANKLIN, Tenn.--(BUSINESS WIRE)--Lynch Regenerative Medicine, LLC., (LRM) and its wholly owned subsidiaries LRM Aesthetics, Inc. (LRMA), and LRM WoundCare, Inc. (LRMW), announced today that Charlie Hee, Ph.D., will join its team as Chief Scientific Officer (CSO) across all companies, effective immediately. Dr. Hee is an experienced translational scientist and strategic leader, with more than 20 years of industry and research experience. Trained in tissue engineering, with a doctorate from the...